BioSpace News Archive

MEDNAX, Inc., announced its affiliation with Alfredo Gei MD, P.A., a private maternal-fetal medicine practice based in Houston.

Eli Lilly and Company announced that the company will present positive findings from the Phase 3b/4 SPIRIT-Head-to-Head study in patients with active psoriatic arthritis as a late-breaking abstract at the European Congress of Rheumatology in Madrid, Spain on June 15.

In Phase IIIb DIALIZE trial, 41.2% of LOKELMA patients maintained normal potassium levels pre-dialysis compared to 1% receiving placebo

Ampio Pharmaceuticals, Inc. announced that it received FDA approval of the Company’s special protocol assessment of a clinical protocol titled “A Randomized, Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of an Intra-Articular Injection of Ampion in Adults with Pain Due to Severe Osteoarthritis of the Knee.”

Data are part of the DISCOVER 1 and 2 program, the first Phase 3 studies to evaluate a selective IL-23 p19 inhibitor in the treatment of psoriatic arthritis

Strategic Acquisition Diversifies Company’s Portfolio and Provides New Options for Migraine Patients

Prometic Life Sciences Inc. announced that four abstracts highlighting Prometic’s progress in developing PBI-4050 as a potential treatment for both acute kidney injury and chronic kidney disease will be presented at the 56th Congress of the European Renal Association - European Dialysis and Transplant Association.

Health Canada officials will hold a media technical briefing regarding the next steps in the legalization and regulation of cannabis.

Bristol-Myers Squibb Company announced the presentation of updated data from ELOQUENT-3, the international randomized Phase 2 study evaluating Empliciti plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in patients with relapsed or refractory multiple myeloma.

Axolotl Biologix, a biotechnology leader in regenerative medicine, is thrilled that the General Services Administration (GSA) has added the complete line of Axolotl Biologix’s products to the Federal Supply Schedule (FSS).